CM With MO | CM Without MO | |||||
---|---|---|---|---|---|---|
Fremanezumab | Fremanezumab | |||||
Quarterly (n = 201) | Monthly (n = 198) | Placebo (n = 188) | Quarterly (n = 174) | Monthly (n = 177) | Placebo (n = 188) | |
HIT-6 | ||||||
LSM (SE) | −6.0 (0.7) | −6.9 (0.6) | −4.5 (0.7) | −7.0 (0.7) | − 6.8 (0.64) | −4.5 (0.6) |
LSMD (SE) | − 1.5 (0.7) | −2.4 (0.7) | −2.4 (0.7) | − 2.3 (0.7) | ||
P value | 0.0356 | 0.0009 | 0.0006 | 0.0012 | ||
MSQoL, RFR | ||||||
LSM (SE) | 19.6 (1.8) | 21.4 (1.8) | 14.7 (1.9) | 21.9 (2.0) | 21.6 (2.0) | 14.5 (1.9) |
LSMD (SE) | 4.9 (2.0) | 6.7 (2.0) | 7.4 (2.1) | 7.1 (2.1) | ||
P value | 0.0142 | 0.0008 | 0.0005 | 0.0008 | ||
MSQoL, RFP | ||||||
LSM (SE) | 17.5 (1.7) | 18.4 (1.6) | 14.2 (1.7) | 16.4 (1.7) | 14.2 (1.7) | 10.2 (1.7) |
LSMD (SE) | 3.2 (1.8) | 4.2 (1.8) | 6.2 (1.8) | 3.9 (1.8) | ||
P value | 0.0696 | 0.0200 | 0.0007 | 0.0290 | ||
MSQoL, EF | ||||||
LSM (SE) | 20.2 (2.0) | 22.0 (1.9) | 17.3 (2.0) | 22.4 (2.1) | 19.7 (2.1) | 16.7 (2.1) |
LSMD (SE) | 2.9 (2.2) | 4.7 (2.2) | 5.7 (2.3) | 3.0 (2.3) | ||
P value | 0.1833 | 0.0305 | 0.0118 | 0.1873 | ||
PHQ-9 | ||||||
LSM (SE) | −2.8 (0.4) | −2.3 (0.4) | −2.4 (0.4) | −2.6 (0.4) | −2.3 (0.4) | −1.6 (0.4) |
LSMD (SE) | −0.5 (0.4) | 0.0 (0.4) | −1.0 (0.4) | −0.7 (0.4) | ||
P value | 0.2679 | 0.9678 | 0.0155 | 0.0922 |